vonafexor  (ENYO Pharma)

Journal: Hepatology Communications

Article Title: Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

doi: 10.1097/HC9.0000000000000234

Figure Lengend Snippet: Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH

Article Snippet: , Vonafexor (EYP001a) , Phase 2 , NASH , √ , √ , √ , √ , Enyo Pharma , Ratziu et al .

Techniques:

Journal: Advances in experimental medicine and biology

Article Title: Moving Fast Toward Hepatitis B Virus Elimination

doi: 10.1007/978-981-16-0267-2_5

Figure Lengend Snippet: Drugs with other mechanisms in development

Article Snippet: Vonafexor (EYP001) , Oral , FXR agonist , Enyo Pharma, France , 1 , NCT04365933.

Techniques:

Journal: Journal of Viral Hepatitis

Article Title: Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

doi: 10.1111/jvh.13608

Figure Lengend Snippet: Study design. EYP001, code for the international non‐proprietary name Vonafexor; QD, once daily; B.D., twice daily

Article Snippet: In Part A, patients were randomly assigned using a block randomization algorithm to receive blinded oral Vonafexor (100 mg once daily (o.d.), 200 mg o.d., 200 mg twice daily (b.d.), or 400 mg o.d.), placebo, or open‐label entecavir (0.5 mg o.d., Baraclude ® , Bristol‐Myers Squibb, Clinton, NY) for 29 days (Figure ).

Techniques:

Journal: Journal of Viral Hepatitis

Article Title: Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

doi: 10.1111/jvh.13608

Figure Lengend Snippet: Frequencies of patients with treatment‐related adverse events.

Article Snippet: In Part A, patients were randomly assigned using a block randomization algorithm to receive blinded oral Vonafexor (100 mg once daily (o.d.), 200 mg o.d., 200 mg twice daily (b.d.), or 400 mg o.d.), placebo, or open‐label entecavir (0.5 mg o.d., Baraclude ® , Bristol‐Myers Squibb, Clinton, NY) for 29 days (Figure ).

Techniques:

Journal: Journal of Viral Hepatitis

Article Title: Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

doi: 10.1111/jvh.13608

Figure Lengend Snippet: ALT and virology dynamics in patients with grade 3 or 4 ALT elevation. Treatment allocations per patient: S21–017, 100 mg Vonafexor once daily; S21–018, 200 mg Vonafexor once daily; S21–022, 150 mg Vonafexor twice daily +Peg‐IFNα2a; S42–011, 150 mg Vonafexor twice daily +Peg‐IFNα2a. ALT, alanine transaminase; Peg‐IFNα2a, pegylated‐interferon α2a. Dotted lines are HBV DNA changes and filled lines are ALT changes

Article Snippet: In Part A, patients were randomly assigned using a block randomization algorithm to receive blinded oral Vonafexor (100 mg once daily (o.d.), 200 mg o.d., 200 mg twice daily (b.d.), or 400 mg o.d.), placebo, or open‐label entecavir (0.5 mg o.d., Baraclude ® , Bristol‐Myers Squibb, Clinton, NY) for 29 days (Figure ).

Techniques:

Journal: Journal of Viral Hepatitis

Article Title: Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

doi: 10.1111/jvh.13608

Figure Lengend Snippet: Change in circulating HBsAg in patients after a 4‐week Vonafexor treatment. Mean changes (SD) from day 1 baseline to day 35 of HBsAg (log10 IU/ml). Groups were treated with Vonafexor (red lines), placebo (grey, straight line, circle) or entecavir (blue, straight line, rhombus). Vonafexor 100 mg once daily (straight line square); Vonafexor 200 mg once daily (straight line, triangle); Vonafexor 400 mg once daily (straight line, circle); Vonafexor 200 mg twice daily (straight line, cross); Vonafexor 300 mg daily combined with Peg‐IFNα2a (dotted line, rhombus); Vonafexor 150 mg twice daily combined with Peg‐IFNα2a (dotted line, square); placebo with Peg‐IFNα2a (dotted line, circle). HBsAg, hepatitis B surface antigen. Significance: *indicates p < .05 for change from baseline. # indicates p < .05 vs. placebo. o indicates p < .05 for change from baseline and vs. Placebo

Article Snippet: In Part A, patients were randomly assigned using a block randomization algorithm to receive blinded oral Vonafexor (100 mg once daily (o.d.), 200 mg o.d., 200 mg twice daily (b.d.), or 400 mg o.d.), placebo, or open‐label entecavir (0.5 mg o.d., Baraclude ® , Bristol‐Myers Squibb, Clinton, NY) for 29 days (Figure ).

Techniques:

Journal: Journal of Viral Hepatitis

Article Title: Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

doi: 10.1111/jvh.13608

Figure Lengend Snippet: Change in circulating HBV DNA in patients after a 4‐week Vonafexor treatment. Mean changes (SD) from day 1 baseline to day 35 of HBV DNA (log10 IU/ml). Groups were treated with Vonafexor (red lines), placebo (grey, straight line, circle) or entecavir (blue, straight line, rhombus). Vonafexor 100 mg once daily (straight line square); Vonafexor 200 mg once daily (straight line, triangle); Vonafexor 400 mg once daily (straight line, circle); Vonafexor 200 mg twice daily (straight line, cross); Vonafexor 300 mg daily combined with Peg‐IFNα2a (dotted line, rhombus); Vonafexor 150 mg twice daily combined with Peg‐IFNα2a (dotted line, square); placebo with Peg‐IFNα2a (dotted line, circle). HBV, hepatitis B virus. Significance: *indicates p < .05 for change from baseline. #indicates p < .05 vs. placebo. o indicates p < .05 for change from baseline and vs. Placebo

Article Snippet: In Part A, patients were randomly assigned using a block randomization algorithm to receive blinded oral Vonafexor (100 mg once daily (o.d.), 200 mg o.d., 200 mg twice daily (b.d.), or 400 mg o.d.), placebo, or open‐label entecavir (0.5 mg o.d., Baraclude ® , Bristol‐Myers Squibb, Clinton, NY) for 29 days (Figure ).

Techniques: Virus